H
Loading...
Loading...
CDC PLACES (2023, crude) estimates 9.7% of adults in San Francisco have diagnosed diabetes — 2.3 points below the U.S. 12% figure. Census population 873,965. California Medicare wound biologics: Noridian Healthcare Solutions (JE). Hawk Medical is a national HCT/P 361 and wound-care distributor serving licensed San Francisco clinics — not a walk-in office.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18. Hawk Medical ships nationwide — this is not a San Francisco storefront.
Extracellular Matrix (ECM) Therapy in San Francisco, CA for clinics & physicians. ECM therapy products pro… Compliance support & pricing — contact Hawk Medical.
CDC PLACES (2023, crude) estimates 9.7% of adults in San Francisco have diagnosed diabetes — 2.3 points below the U.S. 12% figure. Census city-proper population is 873,965. If you are adding extracellular matrix therapy, start with that epidemiology and with Noridian Healthcare Solutions (JE) — not with a “near me” clinic listing. Hawk Medical ships nationwide; Joe Bradley’s own practice uses the same product classes.
National Extracellular Matrix (ECM) Therapy notes (how the product actually works)CDC PLACES (2023, crude) estimates 9.7% of adults in San Francisco have diagnosed diabetes — 2.3 points below the U.S. 12% figure. Adult obesity in San Francisco is 17.5% (CDC PLACES 2023). That shows up in wound offloading and in joint-preservation volume — not as a slogan. Adult arthritis here is 16.7% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Payer geography: JE / Noridian Healthcare Solutions, sibling states HI, NV. California Department of Public Health is the public-health home. We will not mash those grains into a fake “demand score.”
Vendor consolidation is boring on purpose: one account, IFUs filed, JE articles mapped. 6.6% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Pricing scripts have to match that mix. We will help write them. We will not book your patients.
CDC PLACES (2023, crude prevalence) estimates 9.7% of adults — 2.3 points below the U.S. 12% figure. Obesity is 17.5%; arthritis is 16.7%. That is place-level BRFSS modeling, not a clinic census and not a San Francisco trial.
California is JE. A sister clinic in another state may be a different contractor with different CTP articles. Do not assume one utilization policy ports. We map both if you operate across MACs.
No. Hawk Medical does not distribute products as “stem cell therapy.” HCT/P 361 allografts are regulated under 21 CFR 1271 for homologous use and minimal manipulation. PRP is autologous. Marketing that blurs those lanes is a compliance problem in every state, including California.
California is in CMS MAC JE, administered by Noridian Healthcare Solutions. CTP and skin-substitute coverage is written at the MAC level. Confirm the current LCD/article before you set utilization — we help practices map product to those rules; we do not override them.
If you operate in California and another MAC state, say it on the first call. JE will not port 1:1. We would rather split utilization than watch a sister clinic copy San Francisco tickets into the wrong jurisdiction.
Contact us to learn how Hawk Medical supports practices in San Francisco, CA.
Hawk Medical is a national distributor. Joe Bradley’s clinic uses the same product classes. What is local for San Francisco is JE geography and published epidemiology — not a street address.
CDC PLACES 2023 crude rate for San Francisco — 2.3 points below the U.S. 12% figure. Planning input, not an outcomes claim.
California Part B wound biologics follow this contractor (siblings: HI, NV). We train to the articles. We do not write coverage.
PLACES crude adult arthritis in San Francisco. Useful for joint-program math; still needs a diagnosis and privileging.
No San Francisco storefront. Joe Bradley is an active practice owner. extracellular matrix therapy stays in its regulatory lane — not “FDA-approved stem cell therapy.”
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.